Zhang Lisa, Gaskins Kelli, Yu Zhiya, Xiong Yin, Merino Maria J, Kebebew Electron
1 Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute , National Institutes of Health, Bethesda, Maryland.
Thyroid. 2014 Apr;24(4):695-704. doi: 10.1089/thy.2013.0149. Epub 2014 Mar 10.
Mouse models of metastatic human cancers are important tools in preclinical studies for testing new systematic therapies and studying effectors of cancer metastasis. The major drawbacks of current mouse models for metastatic thyroid cancer are that they have low metastasis rates and do not allow in vivo tumor detection. Here, we report and characterize an in vivo detectable metastasis mouse model of human thyroid cancer using multiple thyroid cancer cell lines.
Human anaplastic thyroid cancer cell lines 8505C, C-643, SW-1736, and THJ-16T; follicular thyroid cancer cell lines FTC-133, FTC-236, and FTC-238; and Hürthle cell carcinoma cell line XTC-1 were transfected with a linearized pGL4.51[luc2/CMV/Neo] vector or transduced with lentivirus containing Luc2-eGFP reporter genes. The stably transfected cells were injected intravenously into NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/SzJ mice. Tumors were detected with an in vivo imaging system-Xenogen IVIS. Vemurafenib, a BRAF inhibitor, was used to treat lung metastases generated from 8505C-Luc2 cells with a BRAF(V600E) mutation to test the accuracy of the model to evaluate response to therapy.
Intravenous injection of as few as 30,000 8505C-Luc2 cells produced lung metastases in 100% of the injected mice, and many of these mice also developed bone metastases at a later stage of the disease. Similarly, metastatic tumors also developed in all mice injected with C-643-Luc2, THJ-16T-Luc2, FTC-133-Luc2, FTC-236-Luc2, FTC-238-Luc2, and XTC-1-Luc2 cells. The metastases were easily detectable in vivo, and tumor progression could be dynamically and accurately followed and correlated with the actual tumor burden. Furthermore, disease progression could be easily controlled by adjusting the number of injected cells. The in vivo treatment of 8505C xenograft lung metastases with vemurafenib dramatically reduced the growth and signal intensity with good correlation with actual tumor burden.
Herein we report an in vivo detectable mouse model of metastatic human thyroid cancer that is reliable and reproducible. It will serve as a useful tool in the preclinical testing of alternative systematic therapies for metastatic thyroid cancer, and for functional studies of thyroid cancer tumor biology in vivo.
转移性人类癌症的小鼠模型是临床前研究中测试新的全身治疗方法和研究癌症转移效应器的重要工具。当前转移性甲状腺癌小鼠模型的主要缺点是转移率低且无法进行体内肿瘤检测。在此,我们报告并描述了一种使用多种甲状腺癌细胞系的可体内检测的人类甲状腺癌转移小鼠模型。
将线性化的pGL4.51[luc2/CMV/Neo]载体转染人未分化甲状腺癌细胞系8505C、C - 643、SW - 1736和THJ - 16T;滤泡状甲状腺癌细胞系FTC - 133、FTC - 236和FTC - 238;以及许特耳细胞瘤细胞系XTC - 1,或用含有Luc2 - eGFP报告基因的慢病毒进行转导。将稳定转染的细胞静脉注射到NOD.Cg - Prkdc(scid)Il2rg(tm1Wjl)/SzJ小鼠体内。用体内成像系统 - Xenogen IVIS检测肿瘤。使用BRAF抑制剂维莫非尼治疗由具有BRAF(V600E)突变的8505C - Luc2细胞产生的肺转移,以测试该模型评估治疗反应的准确性。
静脉注射低至30,000个8505C - Luc2细胞,100%的注射小鼠发生肺转移,其中许多小鼠在疾病后期还发生了骨转移。同样,所有注射C - 643 - Luc2、THJ - 16T - Luc2、FTC - 133 - Luc2、FTC - 236 - Luc2、FTC - 238 - Luc2和XTC - 1 - Luc2细胞的小鼠也都发生了转移性肿瘤。转移灶在体内易于检测,肿瘤进展可动态、准确地跟踪,并与实际肿瘤负荷相关。此外,通过调整注射细胞数量可轻松控制疾病进展。用维莫非尼对8505C异种移植肺转移进行体内治疗,显著降低了肿瘤生长和信号强度,与实际肿瘤负荷具有良好的相关性。
在此我们报告了一种可靠且可重复的可体内检测的人类转移性甲状腺癌小鼠模型。它将作为转移性甲状腺癌替代全身治疗方法临床前测试以及体内甲状腺癌肿瘤生物学功能研究的有用工具。